Gene

Fosun's Next Step: "Deep Mining" for Stable Profits

Retrieved on: 
четверг, марта 28, 2024
Cell, World Health Organization, NMPA, Club Med, Growth, DLBC, Fashion Group International, Mining, KOD, Breast cancer, Gene, National Medical Products Administration, Tourism, Snow, Happiness, Leonardo da Vinci, HKEX, SCLC, Research, Marketing, Fosun Pharma, Lithium, Ice, FTG, Carcinoma, European, Patient, Artesunate, Letter, COVID-19, Fine chemical

With the implementation of the business streamlining strategy, Fosun divested some non-core businesses that had previously provided stable cash flows.

Key Points: 
  • With the implementation of the business streamlining strategy, Fosun divested some non-core businesses that had previously provided stable cash flows.
  • The subsequent improvement in cash flow has brought market attention to how Fosun will sustain stable profit growth as it did over the past decade.
  • The results announcement shows that Fosun's focus on its core businesses in the household consumption sector has gradually yielded results.
  • Leveraging on the two core growth drivers of innovation and globalization, Fosun has continued to deepen its efforts in advantageous industries and reap more stable profits.

Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates

Retrieved on: 
четверг, мая 9, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, FDA, Society, Cancer, Skin, Safety, Research, Joint, Research and development, IRB, Cell, Administration, IND, LEKTI, ASCO, Ichthyosis, Patent, Patient, Gene, Bayer, Prevalence, Rash, Quarter, EGFR, G&A, Netherton syndrome, BTK, Chemotherapy, Pharmaceutical industry

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended March 31, 2024, and provided a business update.

Key Points: 
  • Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended March 31, 2024, and provided a business update.
  • Moreover, preclinical evidence suggests that ATR-12 can markedly reduce IL-36g, a pro-inflammatory cytokine implicated in Netherton syndrome, further validating the potential of our approach.
  • Net Loss was $2.9 million for the quarter ended March 31, 2024, compared to $2.5 million for the comparable period in 2023.
  • Cash and cash equivalents: As of March 31, 2024, the Company had cash and cash equivalents of $3.0 million.

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Retrieved on: 
четверг, мая 9, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, STAC, FDA, CTA, Haemophilia, Enzyme replacement therapy, Kite, Investment, Nav1.7, Fabry disease, Poster, Disease, ERT, Sigma-Aldrich, STAAR, Health care, MAA, Partnership, Sangamo Therapeutics, MINT, AAV, Ligand Pharmaceuticals, IND, Tauopathy, Novartis, DNA, Patient, Pivotal, DSM-IV codes, EMA, Prion, BBB, Genome, BLA, MHRA, Manuscript, BioRxiv, Capsid, Modularity, Biogen, Therapy, Food and Drug Administration, European Medicines Agency, Gene, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
  • “We are pleased with the progress being made in business development discussions across our portfolio, including our Fabry disease program.
  • An IND submission is expected in the fourth quarter of 2024.
  • Revenues for the first quarter ended March 31, 2024 were $0.5 million, compared to $158.0 million for the same period in 2023.

PacBio Announces First Quarter 2024 Financial Results

Retrieved on: 
четверг, мая 9, 2024
University, Genetics, Investment, Health, Growth, Disease, Medicine, DSM-IV codes, Genome, Biology, Abraxis BioScience, Gene, Video game

MENLO PARK, Calif., May 9, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2024.

Key Points: 
  • MENLO PARK, Calif., May 9, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2024.
  • Gross profit for the first quarter of 2024 was $11.3 million, representing a 16% increase compared with $9.8 million for the first quarter of 2023 and a gross margin of 29% in the first quarter of 2024 compared to 25% for the first quarter of 2023.
  • Operating expenses totaled $92.6 million for the first quarter of 2024, compared to $101.0 million for the first quarter of 2023.
  • Net loss for the first quarter of 2024 was $78.2 million, compared to a net loss of $88.0 million for the first quarter of 2023.

Labroots Announces the 12th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2024

Retrieved on: 
четверг, мая 9, 2024
Singular, Labroots, Genetics, Genomics, DSM-IV codes, Mass, Networking hardware, Travel, Health, QIAGEN, Doctor of Philosophy, Research, Gene, Scale, NGS, Knowledge, Entrepreneurship, Future, Bio-Rad Laboratories, Algorithm, Diagnosis, History, MPH, Harvard Medical School, Mass General Brigham, Genetic testing, Thermo Fisher Scientific, Vaccine

YORBA LINDA, Calif., May 9, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website and producer of educational virtual events and webinars, proudly announces the upcoming 12th Annual Precision Medicine Virtual Event Series. This premier virtual conference, scheduled for May 15, 2024, invites worldwide experts and enthusiasts to explore the latest innovations and advancements in precision medicine.

Key Points: 
  • Join Labroots on May 15, 2024, for the 12th Annual Precision Medicine Virtual Event Series, exploring the latest in genomics, genetics, and molecular diagnostics, with keynote speakers, dynamic sessions, and opportunities for continuing education.
  • YORBA LINDA, Calif., May 9, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website and producer of educational virtual events and webinars, proudly announces the upcoming 12th Annual Precision Medicine Virtual Event Series .
  • This premier virtual conference, scheduled for May 15, 2024, invites worldwide experts and enthusiasts to explore the latest innovations and advancements in precision medicine.
  • This year's event will dive deep into the cutting-edge areas of genomics, genetics, and molecular diagnostics, pivotal in the ongoing revolution of personalized healthcare.

Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting

Retrieved on: 
четверг, мая 9, 2024
Cancer, Blood, Tissue, Poster, MD, Cell, Hereditary angioedema, KLKB1, Patient, Gene, Society, HAE, Annual general meeting, Therapy, DSM-IV codes, SAN, Vaccine

SAN DIEGO, May 9, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today highlights new preclinical data supporting the potential of its fully non-viral lead genetic medicines programs and related platform technologies. The data was included in three oral and three poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting, being held in Baltimore, MD and virtually on May 7-11, 2024.

Key Points: 
  • The data was included in three oral and three poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting, being held in Baltimore, MD and virtually on May 7-11, 2024.
  • HAE patients have significant unmet need for a durable, effective, and convenient treatment option that eliminates recurrent attacks.
  • P-KLKB1-101 is a fully non-viral investigational gene editing therapy designed to enable high fidelity editing at pre-kallikrein, or KLKB1, for targeted correction of HAE.
  • Poseida also identified a class of amphipathic small molecules called Poseida Delivery Excipients (PDEs) with unique capabilities for enhancing DNA delivery.

Epitor Therapeutics Unveils CasNano: A Compact, All-in-One CRISPR/Cas for Single AAV Therapies at the American Society of Gene & Cell Therapy Annual Meeting

Retrieved on: 
четверг, мая 9, 2024
Dicarboxylic acid, Disorder, CRISPR, Cas, RNA, Cell, AAV, DNA, TET, Demethylation, Gene, Society, Annual general meeting, Therapy, Biotechnology

NEW YORK, May 9, 2024 /PRNewswire/ -- Epitor Therapeutics, a biotechnology pioneer in epigenetic editing, announces the creation of CasNano, a groundbreaking ultracompact Cas protein.

Key Points: 
  • NEW YORK, May 9, 2024 /PRNewswire/ -- Epitor Therapeutics, a biotechnology pioneer in epigenetic editing, announces the creation of CasNano, a groundbreaking ultracompact Cas protein.
  • The company unveiled new data during the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, showcasing over a 20-fold improvement in targeting efficiency via directed evolution of CasNano and innovative re-engineering of the tracrRNA component of the guide RNA.
  • "In addition to its nuclease activity, CasNano can efficiently demethylate, methylate, and activate target genes when catalytically deactivated, with protein effectors attached.
  • "CasNano is 70% smaller than spCas9 and has been engineered to optimize DNA targeting," added Epitor CEO, Dr. Megan McGill.

Kate Therapeutics Unveils Platform and Pipeline Progress at American Society of Gene & Cell Therapy 2024 Annual Meeting

Retrieved on: 
четверг, мая 9, 2024
Mortality, FDA, University, Facioscapulohumeral muscular dystrophy, Mouse, RNA interference, Safety, Tissue, Heart, Animal, Death, MD, Primate, Cell, Duchenne, Science, Disease, Rockefeller University, Patient, Liver, Society, Gene, X-linked myotubular myopathy, Pediatrics, Gene expression, Judgement, Duchenne muscular dystrophy, Capsid, Annual general meeting, SAN, Muscular dystrophy, Vaccine

SAN DIEGO, May 9, 2024 /PRNewswire/ -- Kate Therapeutics Inc. ("KateTx"), a next-generation gene therapy company, will present detailed preclinical efficacy and safety results on its pipeline and platform at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting being held May 7-11, 2024, in Baltimore, MD and virtually. The results support the best-in-class potential of KateTx's newest generation of skeletal muscle- and heart-targeted, liver de-targeted engineered MyoAAV capsids and gene regulation technology to treat Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), and other devastating genetic skeletal muscle and heart diseases.

Key Points: 
  • KateTx remains on track to select development candidates for additional muscle and cardiac programs in the near term.
  • "KateTx has made significant advances over the past 12 months," said Kevin Forrest, Ph.D., co-founder, president and CEO of KateTx.
  • KateTx's results show the potential to give a one-time gene therapy that potently suppresses DUX4 whenever it is expressed in skeletal muscles.
  • In vitro, the company's MyoAAV-LD mediated RNAi gene therapy candidate showed potent knockdown of DUX4 in FSHD patient myotubes with no off-target effects.

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

Retrieved on: 
четверг, мая 9, 2024
NK, Immunotherapy, Safety, Gene silencing, Rationalization, Research, Cell, Conference, Merkel-cell carcinoma, Downregulation and upregulation, NCT, Skin, Patient, Fox Business, Gene, Hyperpigmentation, Society, Patent, Melanoma, TYR, File, Angela Merkel, Vaccine

MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its Q1 2024 financial results and provided a business update.

Key Points: 
  • MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its Q1 2024 financial results and provided a business update.
  • At March 31, 2024, we had cash of $6.5 million as compared with $8.5 million at December 31, 2023.
  • Net loss was $2.2 million for the three months ended March 31, 2024 as compared with $3.6 million for the three months ended March 31, 2023.
  • The decrease in net loss was primarily due to the changes in research and development expenses, as described above.

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Retrieved on: 
четверг, мая 9, 2024
FDA, Investment, Risk, Destiny, IND, Autoimmune disease, Enrollment, Death, Hospital, GAAP, NK, GEJ, Multiple myeloma, CRS, HER2, Pharmacokinetics, Graft-versus-host disease, Food, Lupus, Data, ADR, BCL, Histology, Therapy, BCMA, Autoimmunity, Safety, Trastuzumab, Research, TRAC, Incidence, IPSC, Chronic lymphocytic leukemia, Acute leukemia, Investigational New Drug, Cancer, Cell, Cmax, Patient, Gene, Society, B-cell lymphoma, BCM, Cytokine release syndrome, Immune system, SLE, Vaccine

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024.

Key Points: 
  • The patient was discharged after a three-day hospital stay without any notable adverse events.
  • The Company will conduct a conference call today, Thursday, May 9, 2024 at 5:00 p.m.
  • ET to review financial and operating results for the quarter and full year ended March 31, 2024.
  • The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com.